Navigation Links
Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
Date:9/3/2008

Martin Cearnal appointed Senior Vice President, Commercial Development

NASHVILLE, Tenn., Sept. 3 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. has appointed industry veteran Martin E. Cearnal as Senior Vice President, Commercial Development. In this newly created position Mr. Cearnal will be directly involved with Cumberland's commercial strategy and business development initiatives.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080903/CLW115 )

Mr. Cearnal brings extensive pharmaceutical experience to his new role. During his 40-year healthcare career, he has been involved with the launches of noteworthy pharmaceutical products including Lipitor(R), Actos(R), Intron-A(R), Straterra(R), Botox(R) and Humira(R). He is the former President and Chief Executive Officer of Physicians World, which became the largest provider of continuing medical education before it was sold to Thomson Healthcare in 2000. He continued his affiliation with the company, serving as President of Thomson Physicians World and Executive Vice President of Thomson Medical Education. Mr. Cearnal began his career at Revlon Healthcare, working in a variety of domestic and international marketing positions and eventually serving as the company's Vice President of Marketing for International Operations. He has been a member of Cumberland's board of directors since 2004.

"We are delighted to have Marty join Cumberland's management team in this important new role," said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. "His broad knowledge of the pharmaceutical industry and considerable expertise will be a great asset to our company."

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company that develops and markets branded, prescription products for targeted physician segments, including hospital acute care and gastroenterology. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information, please visit the Cumberland Pharmaceuticals web site at http://www.cumberlandpharma.com.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):